Is semaglutide the same as Ozempic? Semaglutide is the drug molecule; Ozempic is one branded product made by Novo Nordisk that contains it. The words overlap, but they do not mean the same thing. That distinction matters even more with compounded semaglutide: a prescription may name semaglutide base, yet the pharmacy-made preparation is not Ozempic, not a generic Ozempic, and not interchangeable with an Ozempic pen.
Is semaglutide the same as Ozempic in practical terms?
Think of semaglutide as an ingredient name and Ozempic as a complete product identity. Current Ozempic labeling identifies semaglutide as the active ingredient and includes both a once-weekly injection-pen presentation and once-daily tablet presentations; the earlier 2025 injection prescribing information describes the pen format. Ozempic's label covers specified uses in adults with type 2 diabetes, including glycemic control and certain cardiovascular and kidney-risk outcomes.
| Term | What it identifies | What it does not establish |
|---|---|---|
| Semaglutide | A GLP-1 receptor agonist molecule | Brand, manufacturer, dosage form, concentration or indication |
| Ozempic | A Novo Nordisk semaglutide product with its own label | Every medicine or vial that contains semaglutide |
| Compounded semaglutide | An individualized pharmacy preparation made on a prescription | Ozempic, an approved generic, or automatic equivalence to a brand pen |
Wegovy and Rybelsus are other semaglutide names readers encounter; the semaglutide brand-name guide tracks the product lineup without treating the names as synonyms.
The clinical programs also show why product context matters. SUSTAIN-6, reported in the New England Journal of Medicine in 2016, studied once-weekly 0.5 mg or 1.0 mg semaglutide in 3,297 adults with type 2 diabetes at high cardiovascular risk for 104 weeks (Marso et al.). STEP 1, reported in the same journal in 2021, studied 2.4 mg once weekly with lifestyle intervention in 1,961 adults with overweight or obesity without diabetes for 68 weeks (Wilding et al.). The molecule was semaglutide in both; the population, dose and intended product label were not the same.
Is compounded semaglutide the same as Ozempic?
A compounded semaglutide preparation is not Ozempic. A pharmacy may prepare a prescription that names semaglutide base, the molecule identified on the Ozempic label, but that does not turn the finished preparation into Ozempic. Manufacturer, inactive ingredients, concentration, container, delivery device and quality documentation can all differ. A compounded vial is also prepared for an individual prescription rather than supplied as Novo Nordisk's branded pen.
Semaglutide through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA's current GLP-1 compounding page says the agency does not review compounded drugs for safety, effectiveness or quality before marketing. That is a finished-product distinction, not a claim that the word semaglutide belongs only to one brand.
In a February 2026 warning letter, FDA treated a seller's “same active ingredient” marketing as false or misleading because it implied compounded products had been reviewed like approved products (FDA warning letter). The defensible comparison is specific. The prescription and pharmacy label identify what was ordered and dispensed; neither the product name nor a website slogan proves equivalence to Ozempic. What compounded semaglutide means explains the pharmacy process in more depth.
A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision belongs to the patient and clinician.
Semaglutide base is not a semaglutide salt
This is the chemical detail that can change the answer. In warnings issued in 2023 and 2024, and still posted as of September 2026, FDA said it was aware of compounders using semaglutide sodium or semaglutide acetate. The agency describes those salt forms as different active ingredients from the semaglutide base used in approved products. It also says it lacks information showing the salts have the same chemical and pharmacologic properties and is unaware of a lawful basis for their use in compounding.
A label that says only “semaglutide” therefore deserves more scrutiny than one that clearly identifies the ingredient form. The useful comparison points are the exact active ingredient, dosage form, concentration, dispensing pharmacy, beyond-use date and storage instructions. For a specific vial, those documents matter more than whether its packaging resembles a familiar brand.
The pen-versus-vial difference is real
Most people asking this question picture the Ozempic injection pen. Its labeled dose settings and concentration belong to that device. Compounded semaglutide may arrive in a multi-dose vial or another pharmacy-selected format, with a concentration set by that prescription. FDA has reported dosing errors when patients or clinicians confused units, milliliters and milligrams in compounded injectable products. That does not mean every compounded vial is faulty; it means directions for one format should not be borrowed for another. The prescriber sets the dose and the pharmacy's label governs the preparation dispensed.
Semaglutide versus tirzepatide is a different question
Tirzepatide is not another semaglutide brand. It is a separate molecule that activates both GIP and GLP-1 receptors, while semaglutide targets the GLP-1 receptor. Someone comparing treatment options is asking a clinical question, not a brand-name question. The tirzepatide versus semaglutide comparison covers that distinction.
What a prescription relationship changes
The point of a prescription route is accountability for the exact product, not a claim that every semaglutide preparation is identical. At Promise, a licensed U.S. provider reviews every request and may prescribe only when medically appropriate; not everyone qualifies. If prescribed, a licensed U.S. compounding pharmacy prepares and labels the medication, and follow-up remains connected to the clinical relationship.
That review can account for medical history, current medicines, the intended formulation and whether its delivery format can be used safely. It also creates a place to resolve an ambiguous label or a mismatch between the prescribed concentration and the product received. Grey-market vials sold without a prescription do not provide that chain of responsibility.
The short answer stays simple: Ozempic contains semaglutide, but semaglutide is broader than Ozempic. A compounded preparation must be evaluated as its own prescribed and pharmacy-documented product, never assumed to be a substitute pen under a different name.